Marker Therapeutics, Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $0.84
- 52-Week Range
- $0.81 – $2.46
- Market Cap
- $14.23M
- P/E (TTM)
- —
- EPS (TTM)
- -0.39
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.85
- PEG Ratio
- —
- Return on Equity
- -59.21%
- Return on Assets
- -38.69%
- Gross Margin
- 7.47%
- Operating Margin
- -457.96%
- Profit Margin
- 0.00%
- Current Ratio
- 6.26
- Debt/Equity
- —
- Total Debt
- $0.00
- Free Cash Flow
- $-7.18M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $5.19M
Market Snapshot
About
Clinical-stage immuno-oncology company developing T cell-based therapies to treat hematologic malignancies and solid tumors. Lead programs utilize multi-targeted autologous tumor infiltrating lymphocytes (TIL) designed to recognize and kill cancer cells with multiple antigens. Focus on accessible off-the-shelf solutions.